Cristian Alejandro Benitez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cristian Alejandro Benitez has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Estevez
Hospital de Alta Complegidad El Cruce, Florencio Varela, Argentina
1 shared publication Alfaro María Agustina
Fundación Articular, Argentina; Hospital Nacional Alejandro Posadas, Argentina
1 shared publication- Analia Dellepiane
CEMEC, Casilda, Santa Fe, Argentina
1 shared publication - Antonis Fanouriakis
Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece
1 shared publication Apostolos Perelas
Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA
1 shared publication- Augusto Martín Riopedre
Hospital Argerich: Hospital General de Agudos Dr Cosme Argerich
1 shared publication
Latest Publications
- 25 August 2026
- Published by Elsevier in Medicina Clinica
- Vol. 166 (10) , 107569
Miopatía por superposición anti-PM/Scl tratada exitosamente con upadacitinib
- 25 August 2026
- Published by Elsevier in Medicina Clinica
- Vol. 166 (10) , 107569
Miopatía por superposición anti-PM/Scl tratada exitosamente con upadacitinib
- Open Access
- 26 June 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC)
Background: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases that include dermatomyositis, polymyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy in both adult and juvenile populations. Interstitial lung disease (ILD) is a common and serious complication of IIM, with a highly variable clinical course ranging from indolent disease to rapidly progressive respiratory failure, often influenced by underlying myositis-specific autoantibody profiles. Despite the substantial morbidity and mortality associated with IIM-ILD in both adults and children, high-quality evidence to guide clinical management remains limited. A major barrier to progress in this field is the lack of standardized disease nomenclature and uniform diagnostic or classification criteria, which hampers cohort development, limits comparability across studies, and restricts generalizability of findings. To address this gap, we will conduct a systematic review to inform a consensus-based disease definition for adult and juvenile IIM-ILD, with detailed methodology outlined in this protocol. This review will not evaluate prognosis, treatment, or clinical outcomes, but instead focus exclusively on how IIM-ILD is defined and operationalized across studies. Methods: Following PRISMA 2020 statement and Cochrane methodology, we will search PubMed, EMBASE, Scopus, Cochrane Systematic Reviews, and Cochrane Central from inception to June 30, 2025, using a ‘‘Peer Review of Electronic Search Strategies (PRESS)’’—validated strategy. Eligible studies will include randomized controlled trials (RCTs), cohort and case–control studies, systematic reviews, meta-analyses, guidelines, and consensus statements explicitly reporting IIM-ILD definitions in human participants of all ages. Study selection will be performed in Covidence using predefined criteria. Data extraction will capture case definitions, classification criteria, diagnostic methods, ILD patterns, autoantibody profiles, and study characteristics. Quantitative synthesis will summarize the frequency and components of definitions where possible; otherwise, a structured narrative synthesis will be performed. Discussion: Our systematic review protocol is the first comprehensive attempt at synthesizing the highly heterogenous disease nomenclature currently employed in adult and juvenile IIM-ILD literature. Findings will map areas of agreement and inconsistency in existing definitions, forming an evidence base for subsequent consensus processes, such as Delphi, to establish standardized nomenclature. Harmonized definitions are expected to improve research reproducibility, facilitate multicentric collaboration, and improve patient stratification in clinical practice and trials. Systematic review registration: PROSPERO ID: 1129967.
- 26 June 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessDefining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC)
Background: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases that include dermatomyositis, polymyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy in both adult and juvenile populations. Interstitial lung disease (ILD) is a common and serious complication of IIM, with a highly variable clinical course ranging from indolent disease to rapidly progressive respiratory failure, often influenced by underlying myositis-specific autoantibody profiles. Despite the substantial morbidity and mortality associated with IIM-ILD in both adults and children, high-quality evidence to guide clinical management remains limited. A major barrier to progress in this field is the lack of standardized disease nomenclature and uniform diagnostic or classification criteria, which hampers cohort development, limits comparability across studies, and restricts generalizability of findings. To address this gap, we will conduct a systematic review to inform a consensus-based disease definition for adult and juvenile IIM-ILD, with detailed methodology outlined in this protocol. This review will not evaluate prognosis, treatment, or clinical outcomes, but instead focus exclusively on how IIM-ILD is defined and operationalized across studies. Methods: Following PRISMA 2020 statement and Cochrane methodology, we will search PubMed, EMBASE, Scopus, Cochrane Systematic Reviews, and Cochrane Central from inception to June 30, 2025, using a ‘‘Peer Review of Electronic Search Strategies (PRESS)’’—validated strategy. Eligible studies will include randomized controlled trials (RCTs), cohort and case–control studies, systematic reviews, meta-analyses, guidelines, and consensus statements explicitly reporting IIM-ILD definitions in human participants of all ages. Study selection will be performed in Covidence using predefined criteria. Data extraction will capture case definitions, classification criteria, diagnostic methods, ILD patterns, autoantibody profiles, and study characteristics. Quantitative synthesis will summarize the frequency and components of definitions where possible; otherwise, a structured narrative synthesis will be performed. Discussion: Our systematic review protocol is the first comprehensive attempt at synthesizing the highly heterogenous disease nomenclature currently employed in adult and juvenile IIM-ILD literature. Findings will map areas of agreement and inconsistency in existing definitions, forming an evidence base for subsequent consensus processes, such as Delphi, to establish standardized nomenclature. Harmonized definitions are expected to improve research reproducibility, facilitate multicentric collaboration, and improve patient stratification in clinical practice and trials. Systematic review registration: PROSPERO ID: 1129967.
- 19 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina
Interleukin-23 inhibitors (IL-23i) are effective in psoriatic arthritis (PsA) in randomized trials; however, real-world data from Latin America remain limited. We described baseline characteristics and treatment line at IL-23i initiation, physician-reported reasons for selecting IL-23 inhibition, and pragmatic effectiveness and persistence at 6 and 12 months in Argentina. Multicenter, observational, retrospective cohort study across seven Argentine sites. Adults with rheumatologist-diagnosed PsA initiating IL-23i (guselkumab or risankizumab) in routine care were included. Baseline demographics, disease duration, domains, key activity measures, prior advanced therapy lines, and physician-reported rationale were abstracted from records. Patients were assessed at ~ 6 and 12 months. Primary outcome was physician-recorded minimal disease activity (MDA); persistence was remaining on IL-23i. Analyses were descriptive, with no inferential/predictive analyses due to sample size. Fifty-five patients were included (48% female; age 56 ± 11 years). Mean PsA duration before IL-23i was 7.7 ± 5.8 years and psoriasis duration 19 ± 11 years. IL-23i was initiated as the 1st, 2nd, or ≥ 3rd advanced line in 26%, 34%, and 39%, respectively; prior TNF inhibitor exposure was 75% and IL-17 inhibitor exposure 25%. Domain involvement was frequent (peripheral 95%, skin 91%, nails 44%, enthesitis 43%, dactylitis 13%, axial 17%). Physicians selected IL-23i mainly for safety (73.9%) and expected skin efficacy (69.6%). MDA was achieved by 70% at 6 months (90% persistence) and 75% at 12 months (80% persistence). In Argentine routine care, IL-23 inhibition achieved high MDA rates with substantial 12-month persistence in complex, treatment-experienced PsA, supporting its pragmatic use in daily practice.
- 19 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina
Interleukin-23 inhibitors (IL-23i) are effective in psoriatic arthritis (PsA) in randomized trials; however, real-world data from Latin America remain limited. We described baseline characteristics and treatment line at IL-23i initiation, physician-reported reasons for selecting IL-23 inhibition, and pragmatic effectiveness and persistence at 6 and 12 months in Argentina. Multicenter, observational, retrospective cohort study across seven Argentine sites. Adults with rheumatologist-diagnosed PsA initiating IL-23i (guselkumab or risankizumab) in routine care were included. Baseline demographics, disease duration, domains, key activity measures, prior advanced therapy lines, and physician-reported rationale were abstracted from records. Patients were assessed at ~ 6 and 12 months. Primary outcome was physician-recorded minimal disease activity (MDA); persistence was remaining on IL-23i. Analyses were descriptive, with no inferential/predictive analyses due to sample size. Fifty-five patients were included (48% female; age 56 ± 11 years). Mean PsA duration before IL-23i was 7.7 ± 5.8 years and psoriasis duration 19 ± 11 years. IL-23i was initiated as the 1st, 2nd, or ≥ 3rd advanced line in 26%, 34%, and 39%, respectively; prior TNF inhibitor exposure was 75% and IL-17 inhibitor exposure 25%. Domain involvement was frequent (peripheral 95%, skin 91%, nails 44%, enthesitis 43%, dactylitis 13%, axial 17%). Physicians selected IL-23i mainly for safety (73.9%) and expected skin efficacy (69.6%). MDA was achieved by 70% at 6 months (90% persistence) and 75% at 12 months (80% persistence). In Argentine routine care, IL-23 inhibition achieved high MDA rates with substantial 12-month persistence in complex, treatment-experienced PsA, supporting its pragmatic use in daily practice.
- 10 June 2025
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 21 (4) , 501851
Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients
- 10 June 2025
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 21 (4) , 501851
Mean corpuscular volume and red cell distribution width as predictors of methotrexate response in RA patients
- Open Access
- 10 November 2023
- Published by Springer Nature in Research Square
Endothelial inflammation in patients with Rheumatoid Arthritis treated with Tofacitinib
Introduction: Cardiovascular involvement is frequent in patients with Rheumatoid Arthritis (RA). The use of tofacitinib has been linked with an increment in cardiovascular events in some populations of RA patients. 18F-Fluorodeoxyglucose Positron Emission Tomography (PET-FDG/TC) has emerged as a sensitive and specific test for the evaluation of vascular wall inflammation. The aim of this study is to evaluate the endothelial vascular inflammation using PET-FDG/TC in patients with active RA initiating tofacitinib, at baseline and after 12 weeks of treatment. Methods Observational, prospective, multicentric study. Consecutive patients with RA with moderate/high activity, bDMARD naïve, that were to start tofacitinib were included. Clinical data, disease activity and analytics were assessed. PET-FDG/TC was performed at baseline (week 0) and at week 12 of tofacitinib treatment. Endothelial inflammation was assessed using SUVmax and TBRmax. Carotid arteries doppler ultrasonography was performed at baseline and week 12 and intima-media thickness was measured. Results 30 patients were included. 70% female, median age 57.5 (IQR 42–65) years old, median RA duration 5 (IQR 2–12) years, Median DAS28ESR 5.24 (IQR 4.6–6.1) median CDAI 27.5 (IQR 20–34). At week 12 of tofacitinib treatment, patients showed a significant decrease in disease activity by DAS28ESR (5.21 vs 3.04, p < 0.0001) and CDAI (26.6 vs 8.80, p < 0.0001) but 18F-FDG uptake in the five evaluated areas showed no significant difference between baseline and week 12 with all explored vascular showing a SUVmax over the prestipulated threshold defining inflammation at baseline. Conclusion In our study, we found no change in vascular inflammation at week 12 of tofacitinib treatment, despite improvement in disease activity.
- 10 November 2023
- Published by Springer Nature in Research Square
Open AccessEndothelial inflammation in patients with Rheumatoid Arthritis treated with Tofacitinib
Introduction: Cardiovascular involvement is frequent in patients with Rheumatoid Arthritis (RA). The use of tofacitinib has been linked with an increment in cardiovascular events in some populations of RA patients. 18F-Fluorodeoxyglucose Positron Emission Tomography (PET-FDG/TC) has emerged as a sensitive and specific test for the evaluation of vascular wall inflammation. The aim of this study is to evaluate the endothelial vascular inflammation using PET-FDG/TC in patients with active RA initiating tofacitinib, at baseline and after 12 weeks of treatment. Methods Observational, prospective, multicentric study. Consecutive patients with RA with moderate/high activity, bDMARD naïve, that were to start tofacitinib were included. Clinical data, disease activity and analytics were assessed. PET-FDG/TC was performed at baseline (week 0) and at week 12 of tofacitinib treatment. Endothelial inflammation was assessed using SUVmax and TBRmax. Carotid arteries doppler ultrasonography was performed at baseline and week 12 and intima-media thickness was measured. Results 30 patients were included. 70% female, median age 57.5 (IQR 42–65) years old, median RA duration 5 (IQR 2–12) years, Median DAS28ESR 5.24 (IQR 4.6–6.1) median CDAI 27.5 (IQR 20–34). At week 12 of tofacitinib treatment, patients showed a significant decrease in disease activity by DAS28ESR (5.21 vs 3.04, p < 0.0001) and CDAI (26.6 vs 8.80, p < 0.0001) but 18F-FDG uptake in the five evaluated areas showed no significant difference between baseline and week 12 with all explored vascular showing a SUVmax over the prestipulated threshold defining inflammation at baseline. Conclusion In our study, we found no change in vascular inflammation at week 12 of tofacitinib treatment, despite improvement in disease activity.